ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
67.673,00
-0,08%
Brent Oil
81,295
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) Notícias

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OKYO
DataHoraFonteTítuloCódigoCompanhia
08/05/202408:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/05/202408:00GlobeNewswire Inc.OKYO Pharma Announces Participation in May 2024 Investor ConferencesNASDAQ:OKYOOKYO Pharma Ltd
30/04/202408:00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)NASDAQ:OKYOOKYO Pharma Ltd
08/04/202420:00GlobeNewswire Inc.OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024NASDAQ:OKYOOKYO Pharma Ltd
02/04/202408:00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryNASDAQ:OKYOOKYO Pharma Ltd
22/03/202408:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101NASDAQ:OKYOOKYO Pharma Ltd
21/03/202408:00GlobeNewswire Inc.OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialNASDAQ:OKYOOKYO Pharma Ltd
20/03/202408:00GlobeNewswire Inc.OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventNASDAQ:OKYOOKYO Pharma Ltd
09/02/202409:36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
31/01/202409:00GlobeNewswire Inc.OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardNASDAQ:OKYOOKYO Pharma Ltd
08/01/202409:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
05/01/202411:30GlobeNewswire Inc.OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024NASDAQ:OKYOOKYO Pharma Ltd
20/12/202319:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OKYOOKYO Pharma Ltd
04/12/202309:00GlobeNewswire Inc.OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol VisitNASDAQ:OKYOOKYO Pharma Ltd
31/10/202308:00GlobeNewswire Inc.OKYO Pharma Announces $5.84 Million Cash Raise and Payables ReductionNASDAQ:OKYOOKYO Pharma Ltd
09/10/202312:34InvestorsHub NewsWireOKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP")NASDAQ:OKYOOKYO Pharma Ltd
09/10/202308:00GlobeNewswire Inc.OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)NASDAQ:OKYOOKYO Pharma Ltd
05/10/202308:00GlobeNewswire Inc.OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")NASDAQ:OKYOOKYO Pharma Ltd
15/09/202308:00GlobeNewswire Inc.OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary SharesNASDAQ:OKYOOKYO Pharma Ltd
14/09/202310:15GlobeNewswire Inc.OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary SharesNASDAQ:OKYOOKYO Pharma Ltd
14/09/202309:45GlobeNewswire Inc.OKYO Pharma Limited Announces Withdrawal of Public OfferingNASDAQ:OKYOOKYO Pharma Ltd
13/09/202317:05GlobeNewswire Inc.OKYO Pharma Announces Public Offering of Ordinary SharesNASDAQ:OKYOOKYO Pharma Ltd
08/09/202308:04InvestorsHub NewsWireOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
30/08/202308:00GlobeNewswire Inc.OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)NASDAQ:OKYOOKYO Pharma Ltd
29/08/202308:00GlobeNewswire Inc.OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value RuleNASDAQ:OKYOOKYO Pharma Ltd
25/08/202312:33Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:OKYOOKYO Pharma Ltd
15/08/202310:00GlobeNewswire Inc.OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023NASDAQ:OKYOOKYO Pharma Ltd
31/07/202318:15Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:OKYOOKYO Pharma Ltd
28/07/202318:25Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:OKYOOKYO Pharma Ltd
28/07/202318:25GlobeNewswire Inc.OKYO Pharma Announces Proposed Public Offering of Ordinary SharesNASDAQ:OKYOOKYO Pharma Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:OKYO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
BOV
RNEW4
RENOVA PN
BOV
OIBR3
OI ON
BOV
MGLU3
MAGAZINE LUIZA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados